Ancillary Course Info

The NLA's Masters in Lipidology course provides an advanced examination of the core curriculum in Clinical Lipidology. This course is designed for any health care professional with experience in Lipidology who desires advanced training. Experts in the field of Lipidology will lecture on advanced concepts and guide participants through interactive learning scenarios that provide tools and skills to further advance personal standards of practice. It is recommended that attendees have already completed preparatory coursework (eg Foundations of Lipidology or similar core curriculum training).

This course is particularly useful to explore the details of Clinical Lipidology and is appropriate for clinicians from the full spectrum of clinical experience including Physicians, Physician Assistants, Nurse Practitioners, Pharmacist, Exercise Physiologists, and Dietitians who are in any phase of training, or even experienced physicians who are looking to take a deeper dive into Lipidology.

Masters in Lipidology is offered as a 2-day course prior to NLA meetings (Clinical Lipid Updates [CLU] and Scientific Sessions).

2023 Course Dates:

December 1-2, 2023
Virtual

To register Click Here

Course Curriculum:

Advanced Lipoprotein Metabolism and Genetic Disorders
Obesity, Diabetes Mellitus, and the Metabolic Syndrome
RCT Interpretation and Statistics for the Clinical Lipidologist
Pharmacology of Lipid Altering Drugs
Evidence Based Nutrition and Lifestyle Modifications
Randomized Controlled Trials and Lipid Altering Therapies
Emerging Therapies and Drug Discovery
Evidence Based Guidelines in Lipid Management for ASCVD Risk Reduction
Complex Cases and Consultative Lipidology

Target Audience
This activity is designed to meet the needs of physicians, physician assistants, pharmacists, registered nurses, advance practice registered nurses, nurse practitioners and registered dietitians with expertise in Lipidology looking for further advanced training.

Pricing*
Member cost: $750
Non-Member cost: $1,250
Trainee cost: $395

*Pricing subject to change

At the conclusion of this activity, participants should be able to:

  • Describe the vascular biology and pathophysiology of atherosclerosis.
  • Review the role of biomarkers & subclinical atherosclerosis testing (imaging) in assessment & prevention of ASCVD.
  • Assess guideline application and practical use of biomarkers and imaging in clinical practice.
  • Assess the impact of diet, exercise and behavior modifications on cardiovascular risk and risk factors.
  • Interpret evidence from literature on dietary cholesterol.
  • Compose a treatment plan for patients incorporating dietary changes.
  • Examine historic investigations into clinical lipidology and describe their current clinical application.
  • Review lipid-altering drugs in development.
  • Describe genetic disorders affecting lipoprotein metabolism.
  • Diagnose genetic disorders using lipid profiles.
  • Compare and contrast the mechanism of action, pharmacokinetics, and efficacy of approved drugs for the management of dyslipidemia.
  • Identify the frequency and secondary causes of statin intolerance and treatment options for statin intolerant patients.
  • Assess the efficacy and safety of lipid-altering drugs.
  • Interactive group review of a sentinel article in clinical lipidology.
  • Improve skills in critically evaluating journal articles.
  • Describe evaluation criteria for the classification of patients with metabolic syndrome and/or obesity.
  • Provide applicable clinical diabetes and obesity updates for the clinical lipidologist.
  • Appraise treatment approaches for dyslipidemia in specific populations based on age, gender, ethnicity, and cultural variables.
  • Evaluate data from key clinical trials of lipid-altering drug therapies used in cardiovascular disease prevention.
  • Discuss the evidence base for the use of statin and non-statins in the primary & secondary prevention of ASCVD.
  • Evaluate the evidence base for the use of non-statin therapy in combination with moderate to high intensity statin therapy.
  • Review the treatment goals & targets of different lipid guidelines.
  • Compose a treatment plan for patients with complex lipid disorders.
  • Implement current evidence-based guidelines to create treatments plans for patients with complex lipid disorders.
  • Distinguish roles in a team-based approach to care.
  • Discuss strategies to improve the knowledge, skills or performance of the healthcare team.

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 14 AMA PRA Category 1 Credits™ MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

The National Lipid Association is accredited by the American Nurses Credentialing Center (ANCC), the Accreditation Council for Pharmacy Education (ACPE), and the Accreditation Council for Continuing Medical Education (ACCME), to provide continuing education for the healthcare team.

Physician Credit Designation Statement
The National Lipid Association designates this Live Activity for a maximum of 14 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physician Assistants
NCCPA accepts AMA PRA Category I Credit™ from organizations accredited by ACCME.

Dietitians
The National Lipid Association is a Continuing Professional Education (CPE) Accredited Provider with the Commission on Dietetic Registration (CDR). Registered dietitians (RDs) and dietetic technicians, registered (DTRs) will receive 14 continuing professional education units (CPEUs) for completion of this program/ materials. CDR Accredited Provider #NL0002.

CE Credit provided by The National Lipid Association
Pharmacists
Universal Activity Number - JA0007192-0000-23-005-L01-P(Application)
This activity has been approved for 14 contact hours (1.4 CEUs) of the Accreditation Council for Pharmacy Education.

Nursing
The maximum number of hours awarded for this CE activity is 14.

Pharmacotherapy contact hours for Advance Practice Registered Nurses to be determined.

Criteria for Success
Statements of credit will be awarded based on the participant's attendance and submission of the activity evaluation form. A statement of credit will be available upon completion of an online evaluation/ claimed credit form at www.lipid.org/cme.

For Pharmacists:
Upon receipt of the completed activity evaluation form, transcript information will be available at www.mycpemonitor.net within 4 weeks.

Disclosure Statement
It is the policy of NLA to ensure independence, balance, objectivity, scientific rigor, and integrity in all of its continuing education activities. The faculty must disclose to the participants any significant relationships with commercial interests whose products or devices may be mentioned in the activity or with the commercial supporter of this continuing education activity. Identified conflict of interest is resolved by NLA prior to accreditation of the activity. NLA planners and reviewers have no relevant financial relationships to disclose.

Commercial Support
Full notification of commercial support will be provided in the activity materials.

Anne Carol Goldberg, MD, FACP, MNLA

Chief Science Officer, National Lipid Association
Professor of Medicine
Division of Endocrinology, Metabolism and Lipid Research
Department of Medicine
Washington University School of Medicine
St. Louis, MO

Peter H. Jones, MD, MNLA

Associate Professor
Baylor College of Medicine
Houston, TX
Diplomate, American Board of Clinical Lipidology

Kevin C. Maki, PhD, CLS, FNLA

Immediate Past President, National Lipid Association
President and Chief Scientist
Midwest Biomedical Research
Addison, IL & Bonita Springs, FL
Adjunct Professor
Dean’s Eminent Scholar
Indiana University School of Public Health
Bloomington, IN
Managing Member
Great Lakes Clinical Trials
Chicago, IL

James A. Underberg, MD, MS, MNLA

Clinical Lipidology
Clinical Assistant Professor of Medicine
NYU School of Medicine & NYU Center for Prevention of Cardiovascular Disease
Director, Bellevue Hospital Lipid Clinic
Immediate Past- President, National Lipid Association
New York, NY
Diplomate, American Board of Clinical Lipidology

2023 Masters in Lipidology Course - Virtual

Friday, December 1, 2023

Day 1

- All times listed in Central Time
7:30 AM - 7:40 AM Program Overview James A. Underberg, MD, MS, MNLA
7:40 AM - 9:25 AM Advanced Lipoprotein Metabolism and Genetic Disorders James A. Underberg, MD, MS, MNLA
9:25 AM - 9:40 AM Break
9:40 AM - 10:50 AM Obesity, Diabetes Mellitus, and Metabolic Syndrome Peter H. Jones, MD, MNLA
10:50 AM - 11:00 AM Break
11:00 AM - 12:15 PM RCT Interpretation and Statistics for the Clinical Lipidologist Kevin C. Maki, PhD, CLS, FNLA
12:15 PM - 12:45 PM Lunch
12:45 PM - 1:45 PM Pharmacology of Lipid Altering Drugs – Part 1 James A. Underberg, MD, MS, MNLA
1:45 PM - 1:55 PM Break
1:55 PM - 2:55 PM Pharmacology of Lipid Altering Drugs – Part 2 James A. Underberg, MD, MS, MNLA
2:55 PM - 3:10 PM Break
3:10 PM - 5:00 PM Randomized Controlled Trails and Lipid Altering Therapies Peter H. Jones, MD, MNLA

Saturday, December 2, 2023

Day 2

- All times listed in Central Time
7:30 AM - 7:35 AM Day 2 Overview Peter H. Jones, MD, MNLA
7:35 AM - 9:20 AM Evidence Based Nutrition and Lifestyle Modifications Carol F. Kirkpatrick, PhD, MPH, RDN, CLS, FNLA
9:20 AM - 9:30 AM Break
9:30 AM - 10:30 AM Emerging Therapies and Drug Discovery Kevin C. Maki, PhD, CLS, FNLA
10:30 AM - 10:40 AM Break
10:40 AM - 12:15 PM Evidence Based Guidelines in Lipid Management for ASCVD Risk Reduction Daniel E. Soffer, MD, FNLA
12:15 PM - 12:45 PM Lunch
12:45 PM - 2:20 PM Complex Cases and Consultative Lipidology Peter H. Jones, MD, MNLA & James A. Underberg, MD, MS, MNLA
2:20 - 2:25 PM Course Wrap-up